Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Recombinant H7 Influenza Vaccine in Healthy Adults
NCT03038776Phase 1Completed
- Sponsor
- Vaxine
- Start
- Jan 2017
- Primary completion
- Nov 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised trial of Panblok H7 in Avian Influenza (AI) (6 arms), sponsored by Vaxine. Primary endpoints: Seroconversion Rate, Seroprotection Rate and 1 more. Started Jan 2017; status: completed.
02
Drugs
Panblok H7
03
Conditions
Avian Influenza (AI)
Beyond the preview
Go deeper on NCT03038776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03038776.